We transform the most promising oncology innovations into highly competitive opportunities that benefit patients, researchers, investors, and Ontario's economy. Cancer Breakthroughs. Realized.
FACIT’s Prospects Oncology Fund invests in Ontario-developed medical device and novel therapeutic platform technologies
Niche early-stage investment program seeds Ontario’s developing pipeline of oncology assets
FACIT announces investments in Xpan Inc. and innovations from OICR and the University of Toronto...
FACIT congratulates its strategic partner OICR on their recent industrial collaboration with Thermo Fisher Scientific and Genome Canada
New collaboration will develop targeted next generation sequencing (NGS) assays and software to improve cancer management...
$40M in seed investments leverages 19x new capital into Ontario cancer biotechnology commercialization
FACIT’s network of industry partners and investors are becoming increasingly aware of the top-tier quality of Ontario’s innovations, which has been integral in attracting the $750M follow-on investment.
Entrepreneurs from Ontario’s Nanology Labs and Xpan Inc. receive FACIT investment for early-stage cancer innovations
Latest recipients slated to accelerate Ontario’s commercialization momentum are a 2018 finalist and 2019’s winner of FACIT’s Falcons’ Fortunes pitch competition.
FACIT is pleased to announce recent successes in its mission to help bridge the capital gap often experienced by early-stage entrepreneurs.
FACIT congratulates portfolio company Fusion Pharma on the addition of top-tier healthcare investors in support of their cancer-targeting, next-gen radiotherapies.
Ontario First investor FACIT congratulates portfolio company Fusion Pharmaceuticals, a clinical-stage biotech developing novel targeted alpha radiotherapies...
FACIT Features: Triphase Accelerator initiates Phase 1 clinical trial of next-gen ADC for B-cell lymphoma
FACIT congratulates portfolio company Triphase Accelerator on significant clinical development milestone.
Triphase Accelerator has dosed their first patient in a Phase 1 clinical trial of TRPH-222, an anti-CD22 antibody-drug conjugate (ADC) for the treatment of patients with lymphoma.